Tumors expressing estrogen receptor (ER) and/or progesterone receptor (PR) are considered hormone receptor (HR)-positive BC and those expressing the human epidermal growth factor receptor 2 (HER2 or ERBB2) are diagnosed as HER2-positive BC. Here, ERBB2 is linked to breast cancer.